WO2002087591A3 - Use of derivatives of spironolactone like canrenone as anti-fibrogegic drug - Google Patents

Use of derivatives of spironolactone like canrenone as anti-fibrogegic drug Download PDF

Info

Publication number
WO2002087591A3
WO2002087591A3 PCT/EP2002/004211 EP0204211W WO02087591A3 WO 2002087591 A3 WO2002087591 A3 WO 2002087591A3 EP 0204211 W EP0204211 W EP 0204211W WO 02087591 A3 WO02087591 A3 WO 02087591A3
Authority
WO
WIPO (PCT)
Prior art keywords
spironolactone
canrenone
drug
fibrogegic
derivatives
Prior art date
Application number
PCT/EP2002/004211
Other languages
French (fr)
Other versions
WO2002087591A2 (en
Inventor
Massimo Pinzani
Massimo Vanasia
Original Assignee
Gienne Pharma S P A
Massimo Pinzani
Massimo Vanasia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gienne Pharma S P A, Massimo Pinzani, Massimo Vanasia filed Critical Gienne Pharma S P A
Priority to AU2002319135A priority Critical patent/AU2002319135A1/en
Publication of WO2002087591A2 publication Critical patent/WO2002087591A2/en
Publication of WO2002087591A3 publication Critical patent/WO2002087591A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to the use of a spironolactone compound to produce a drug for inhibiting the pro-fibrogenic effect of hepatic stellate cells and vascular smooth muscle cells, particularly in relation to fibrogenesis induced by pro-fibrogenic cytokines. Canrenone, potassium canrenoate, spironolactone and eplerenone are particularly preferred compounds for use in the invention.
PCT/EP2002/004211 2001-04-17 2002-04-16 Use of derivatives of spironolactone like canrenone as anti-fibrogegic drug WO2002087591A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002319135A AU2002319135A1 (en) 2001-04-17 2002-04-16 Use of derivatives of spironolactone like canrenone as anti-fibrogegic drug

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2001MI000821A ITMI20010821A1 (en) 2001-04-17 2001-04-17 USE OF COMPOUNDS DERIVED FROM SPIROLACTONE TO INHIBIT THE PRO-FIBRIGENETIC ACTION OF Hepatic star cells and Muscle cells
ITMI2001A000821 2001-04-17

Publications (2)

Publication Number Publication Date
WO2002087591A2 WO2002087591A2 (en) 2002-11-07
WO2002087591A3 true WO2002087591A3 (en) 2003-01-09

Family

ID=11447515

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/004211 WO2002087591A2 (en) 2001-04-17 2002-04-16 Use of derivatives of spironolactone like canrenone as anti-fibrogegic drug

Country Status (3)

Country Link
AU (1) AU2002319135A1 (en)
IT (1) ITMI20010821A1 (en)
WO (1) WO2002087591A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202013270D0 (en) * 2020-08-25 2020-10-07 Engitix Ltd Anti-fibrotic combination

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4542024A (en) * 1983-07-15 1985-09-17 Schering Aktiengesellschaft 15,16 -Methylene-17α-pregna-4,6-diene-21-carboxylic acid salts, pharmaceutical preparations containing them and a process for their production
WO1995015166A1 (en) * 1993-12-02 1995-06-08 Curators Of The University Of Missouri Use of aldosterone antagonists to inhibit myocardial fibrosis
US6150347A (en) * 1992-04-21 2000-11-21 The Curators Of The University Of Missouri Use of aldosterone antagonists to inhibit myocardial fibrosis
WO2001041535A2 (en) * 1999-12-08 2001-06-14 Pharmacia Corporation Eplerenone crystalline form

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4542024A (en) * 1983-07-15 1985-09-17 Schering Aktiengesellschaft 15,16 -Methylene-17α-pregna-4,6-diene-21-carboxylic acid salts, pharmaceutical preparations containing them and a process for their production
US5668124A (en) * 1992-04-21 1997-09-16 Weber; Karl T. Use of aldosterone antagonists to inhibit myocardial fibrosis
US6150347A (en) * 1992-04-21 2000-11-21 The Curators Of The University Of Missouri Use of aldosterone antagonists to inhibit myocardial fibrosis
WO1995015166A1 (en) * 1993-12-02 1995-06-08 Curators Of The University Of Missouri Use of aldosterone antagonists to inhibit myocardial fibrosis
WO2001041535A2 (en) * 1999-12-08 2001-06-14 Pharmacia Corporation Eplerenone crystalline form

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CALIGIURI ALESSANDRA ET AL: "Inhibition of the sodium/hydrogen exchanger mediates the antifibrogenic effects of canrenone (CR) in human hepatic stellate cells (HSC).", HEPATOLOGY, vol. 30, no. 4 PART 2, October 1999 (1999-10-01), 50th Annual Meeting and Postgraduate Courses of the American Association for the Study of Liver Diseases;Dallas, Texas, USA; November 5-9, 1999, pages 485A, XP001119411, ISSN: 0270-9139 *
LACOLLEY P ET AL: "Prevention of aortic and cardiac fibrosis by spironolactone in old normotensive rats.", JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. UNITED STATES FEB 2001, vol. 37, no. 2, February 2001 (2001-02-01), pages 662 - 667, XP001119401, ISSN: 0735-1097 *
YANG X ET AL: "CYP11B2 expression in rat liver and the effect of spironolactone on hepatic fibrogenesis.", HORMONE RESEARCH. SWITZERLAND 2000, vol. 53, no. 6, 2000, pages 288 - 293, XP001117827, ISSN: 0301-0163 *

Also Published As

Publication number Publication date
ITMI20010821A1 (en) 2002-10-17
WO2002087591A2 (en) 2002-11-07
ITMI20010821A0 (en) 2001-04-17
AU2002319135A1 (en) 2002-11-11

Similar Documents

Publication Publication Date Title
AU2003246810A1 (en) Diphenylpyridine derivatives, the preparation thereof, and pharmaceutical compositions containing said derivatives
AU2002246411A1 (en) Inclusion compounds of fumagillol derivative or its salt, and pharmaceutical compositions comprising the same
ZA200608029B (en) Nitrogenous fused-ring derivatives, medicinal compositions containing the derivatives, and use thereof as drugs
IL175844A0 (en) Improved stability of progestogen formulations
EP1841761A4 (en) Fumagillol derivatives or method for preparation of fumagillol derivatives, and pharmaceutical compositions comprising the same
AU2003262747A1 (en) Compounds, compositions, and methods
IL175953A (en) 3-cycloalkylaminopyrrolidine derivatives, pharmaceutically acceptable salts thereof and compositions comprising the same
AU2002210993A1 (en) Medicinal compositions for concominant use as anticancer agents
IL173807A0 (en) Amphiphilic antioxidant compounds, mitoquinone derivatives and pharmaceutical compositions containing the same
AU2003236135A1 (en) Aralkyl-alcohol peiperazine derivatives and their uses as antidepressant
IL176515A0 (en) 1,3-diphenylprop-2-en-1-one derivative compounds, preparation method thereof and uses of same
WO2006056696A3 (en) 2-alcoxy-3,4,5-trihydroxy-alkylamides, preparation thereof, compositions containing them and use thereof
WO2005051083A3 (en) Molluscicidal and anti-barnacle compounds
WO2006029398A3 (en) All-trans-retinol : all-trans-13,14-dihydroretinol saturase and methods of its use
IL182811A (en) Dicarboxamide derivatives, compositions, uses and methods of preparation thereof
AU2003290507A1 (en) Compounds, compositions and methods
AU2001292331A2 (en) 5-amidino-2-hydroxybenzenesulfonamide derivatives, pharmaceutical compositions containing the same and intermediates for their preparation
AU2001292331A1 (en) 5-amidino-2-hydroxybenzenesulfonamide derivatives, pharmaceutical compositions containing the same and intermediates for their preparation
ZA200606542B (en) 1,3-diphenylprop-2-en-1-one derivative compounds, preparation method thereof and uses of same
AU2003224482A1 (en) Quinoline derivatives as caspase-3 inhibitor, preparation for producing the same and pharmaceutical composition comprising the same
WO2004056832A3 (en) Epothilone derivatives
WO2002087591A3 (en) Use of derivatives of spironolactone like canrenone as anti-fibrogegic drug
WO2004048381A3 (en) Pyrazoloazepine compounds as pharmaceutical agents
AU2003284460A1 (en) Medicinal composition
AUPS317102A0 (en) Transdermal aerosol compositions

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP